Mild Cognitive Impairment Clinical Trial
Official title:
Maintaining Independence and Quality of Life in Aging Adults Through Targeted Cognitive Training
Mild Cognitive Impairment, Alzheimer's Disease and Parkinson's Disease all represent a range
of degenerative conditions that have cognitive impairments which all limit the ability for
older individuals to self-manage care, participate in daily activities and community
participation. The consequences of these progressive diseases increase the requirement for
residential care, associated medical costs and may negatively impact the overall quality of
life and mental health for individuals. According to the Alzheimer Society of Canada, over
the next few decades, more than 1 million Canadian's will be living with decreased cognitive
ability and will require an increased amount of support, whether through family or
institutional sources.
Currently, there are few cognitive programs for individuals diagnosed with mild cognitive
impairment or for individuals wishing to maintain their current level of cognitive ability
which translates to meaningful improvements in daily living and independence, as well as
generalized intelligence. To date, the Watson Centre Society for Brain Health (WCSBH) has
successfully improved cognitive capacity, executive function and quality of life for over 100
individuals following a wide range of brain injury, and currently has a 77% return to work
rate following completion of the full program. The program includes a combination of physical
exercise, cognitive training and mindfulness meditation.
The purpose of the research study is to explore the impact of an interdisciplinary cognitive
rehabilitation program has upon the cognitive functioning and quality of life for individuals
who are assessed to have mild cognitive impairment (MCI). In particular, the aims of this
study include: 1) To evaluate changes in cognition and quality life in older adults with MCI.
2) To explore the potential for intensive cognitive intervention in slowing cognitive
degeneration in older adults with MCI.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | October 31, 2021 |
Est. primary completion date | August 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - T-MoCA score between 19 - 23 Exclusion Criteria: - Potential participants are under the age of 65 years at the time of screening - Scoring results in a range outside of 19-23 on the MoCA - Those who have have a diagnosed illness or diagnosed injury which is known to directly and negatively impact cognition - Are known (legally) to be deemed incapable; unable to appreciate information that is relevant to making decisions or is unable to appreciate the reasonably foreseeable consequences of either making or not making a decision. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Kwantlen Polytechnic University | ABI Wellness Inc, Centre for Aging and Brain Health Innovation, Watson Centre Society for Brain Health |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Montreal Cognitive Assessment | Telephone Montreal Cognitive Assessment (T- MoCA) - non-invasive screening tool which takes approximately 10 minutes to complete. Thirty items assessing multiple cognitive domains are contained in the MoCa: short-term memory; visuospatial abilities via clock drawing; and a cube copy task; executive functioning via an adaptation of Trail Making phonemic fluency, and verbal abstraction; attention, concentration, and working memory via target detection, serial subtraction, digits forward, and digits backward; language via confrontation naming with low-familiarity animals, and repetition of complex sentences; and orientation to time and place (Nasreddine et al., 2005). The MoCA is scored by obtaining an item total. | Pre-post assessment completed 6 months apart with a 6 month follow up | |
Primary | Memory Alteration Test | Memory Alteration Test (M@T) - A non-invasive memory screening test used to discriminate between subjects with subjective memory complaints (SMC) Without objective memory impairment and patients with amnesic mild cognitive impairment (A-MCI) and with Mild Alzheimers disease (AD). (M@T), which is a memory screening test, capable for discriminating between subjects with subjective memory complaints (SMC) (without objective memory impairment) and patients with amnestic mild cognitive impairment (A-MCI) and with mild Alzheimer's disease (AD). This is a cognitive test with high internal consistency and validity, short application (5-10 min), easy to perform and to interpret (Carnero-Pardo et al., 2011a). | Pre-post assessment completed 6 months apart with a 6 month follow up | |
Primary | Mild Cognitive Impairment Questionnaire | Mild Cognitive Impairment Questionnaire (MCQ) -QOL will be measured using the 13-item MCQ tool designed to take 5 minutes to administer. The MCQ tool uses a scale of 0-4 (none, rarely, sometimes, often, or always) to assess two constructs - Practical Concerns and Emotional Concerns. Scores are transformed and presented on a metric of 0 (no problems) to 100 (maximum impact of MCI). Scale scores are interpreted using the following guide: a scale score of 0-20 indicates 'never' experiencing the issue, 21-40 'rarely' experiencing it, 41-60 'sometimes' experiencing it,61-80 'often' experiencing it, 81-100 'always' experiencing it. The MCQ has been shown to have great stability and reliability through test-retest and substantial validity with this population. | Pre-post assessment completed 6 months apart with a 6 month follow up | |
Primary | Neuro-QOL | Neuro-QOL This research tool measures the physical, mental, and social effects experienced by adults with neurological conditions. The measurement takes approximately 30 minutes to complete and will be administered three times. | Pre-post assessment completed 6 months apart with a 6 month follow up | |
Secondary | Qualitative Interviews | Interviews - Semi-structured interviews will occur with all participants in the study including the intervention and the control group with a focus upon lived experience specific to quality of life. | Pre-post assessment completed 6 months apart with a 6 month follow up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |